Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 392 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of... February 24, 2021 As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... February 25, 2021 Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active... October 29, 2025 Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... March 14, 2024 Load more HOT NEWS Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration The Barriers to Care Faced by LGBTQ People With Cancer: An... How to Find a Caregiver When You Have Cancer
